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Abstract: Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (BDDE), derived from the marine 
algae, is a potential α-glucosidase inhibitor for type 2 diabetes treatment. In the present 
study, a synthetic route was established as a valid approach to obtain BDDE. Fluorescence 
spectra, circular dichroism spectra and molecular docking methods were employed to 
elucidate the inhibitory mechanisms of BDDE against α-glucosidase. The results showed 
that BDDE could be prepared effectively and efficiently with the established synthetic 
methods. Synthetic BDDE bound with α-glucosidase and induced minor conformational 
changes of the enzyme. The docking results indicated the interaction between BDDE and 
α-glucosidase was driven by both hydrophobic forces and hydrogen bonds. The docked 
BDDE molecule was completely buried in the α-glucosidase binding pocket with part of 
the molecule reaching the catalytic center and overlapping with the position of glucose, and 
the rest of the molecule extending towards protein surface. This study provides useful 
information for the understanding of the BDDE-α-glucosidase interaction and for the 
development of novel α-glucosidase inhibitors. 
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1. Introduction  
α-Glucosidase, is involved in carbohydrate synthesis and breakdown, plays crucial role in diabetes, 
viral infection and cancer. Due to its diverse bioactivities, α-glucosidase has been considered to be a 
preferred drug target in the pharmaceutical area and a number of α-glucosidase inhibitors have been 
discovered and studied. The clinically used anti-diabetic agents acarbose [1], voglibose, and 
miglitol [2],  inhibit  α-glucosidase competitively in the brush border of the small intestine, and 
consequently delay the hydrolysis of carbohydrates and alleviate postprandial hyperglycemia. 
However, the continuous administration of these agents may cause some adverse effects, such as 
diarrhoea, abdominal discomfort, flatulence [3–5], and hepatotoxicity [6]. It is therefore still necessary 
to develop novel α-glucosidase inhibitors. The therapeutic challenge of type 2 diabetes mellitus 
promotes the search for novel α-glucosidase inhibitors and a number of them have been 
investigated [7–11]. 
One such newly reported group of α-glucosidase inhibitors are the marine natural 
bromophenols  [12–15], which are usually isolated from the marine algae. As the α-glucosidase 
inhibitors, these bromophenols have been reported to inhibit against α-glucosidase with low IC50’s 
(Table 1), and this activity has a close relationship with the Br and phenolic unit in the molecules. One 
of the most potent bromophenol α-glucosidase inhibitors is bis(2,3-dibromo-4,5-dihydroxybenzyl) 
ether (BDDE, Figure 1), which competitively inhibits α-glucosidase with an IC50 of 0.098 μM [12,13,15]. 
BDDE has also been reported to possess anticancer [16], and antibacterial activities [17]. The previous 
promising research results indicate that BDDE represents a novel lead compound for the design of new 
drugs. However, low content in marine algae as well as the difficulty in extraction and separation have 
hindered further investigations of BDDE bioactivities. In addition, few efforts have been contributed to 
explore the interaction between BDDE and α-glucosidase, which is important for dissecting the 
structure-activity relationship for further optimizations. 
In this study, we present a synthetic route that can provide sufficient amounts of BDDE to facilitate 
bioactivity studies, and we further investigate the mechanisms underlying BDDE inhibition using 
fluorescence spectra, circular dichroism (CD) spectra, and molecule docking. 
Table 1. IC50 values and S. cerevisiae α-glucosidase inhibition modes of bromophenols 
purified from different marine algae. 
Marine bromophenol  (μM) Inhibition  mode Reference
Bis(2,3,6-tribromo-4,5-dihydroxybenzyl) ether  0.03  Unknown  [13] 
Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether  0.098  Competitive  [12,13,15] 
2,3,6-Tribromo-4,5-dihydroxybenzyl alcohol  11  Mixed  [15] 
4-Bromo-2,3-dihydroxy-6-hydroxymethylphenyl-2,5-
dibromo-6-hydroxy-3-hydroxymethylphenyl ether 
25 Unknown  [12] 
2,4,6-Tribromophenol 60.3  Mixed  [14] 
2,3-Dibromo-4,5-dihydroxybenzyl alcohol  89  Mixed  [12] 
3-Bromo-4,5-dihydroxybenzyl alcohol  100  Mixed  [13] 
2,4-Dibromophenol 110.4  Mixed  [14] Mar. Drugs 2011, 9  
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Figure 1. Structure of bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (BDDE). 
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2. Results and Discussion  
2.1. Synthesis of BDDE 
The abundance of BDDE in the fresh red algae is very low (about 3 × 10
−3% W/W) [12], which 
makes further investigation difficult. In order to obtain sufficient quantities of pure BDDE, we initiated 
development of an improved synthesis efforts on BDDE. The synthetic route established, shown in 
Scheme 1, was different from the published synthetic methods [18]. Although this route is four steps 
longer, with a total yield of 4.7%, the workup process is convenient and this route avoids   
the instability of the intermediate products and also avoids the production of byproduct   
(2-bromo-4,5-dihydroxybenzyl)(2,3-dibromo-4,5-dihydroxybenzyl) ether, which might complicate the 
purification process. Therefore, it is an alternate efficient approach to obtain the target compound. The 
structure of target compound 7 was confirmed by the following 
1H NMR spectroscopic analysis and 
compared with the data in published literature [12,15]: 
1H NMR (400 MHz, DMSO) δ: 4.344 (4H, s, 
H-7, 7′), 6.939 (2H, s, H-6, 6′), 9.567 (2H, s, HO-5, 5′), 10.085 (2H, s, HO-4, 4′). Compound 7 
exhibited inhibitory activity against α-glucosidase with an IC50 value of 0.116 μM, which was 
consistent with BDDE isolated from marine algae [12,13,15]. Therefore, we established a valid 
synthesis route and provided enough amount of BDDE for the following studies both in vitro and 
in vivo, and also for the evaluations of its other bioactivities. 
Scheme 1. Reagents and Conditions: a: AcOH, Br2, r.t. 2 h; b: MeI, K2CO3, CH3CN, r.t., 
4 h; c: AcOH, Br2, 60 °C overnight; d: NaBH4, MeOH, −20 °C to r.t., 3 h; e: TsCl, Et3N, 
CH3CN, reflux overnight; f: BBr3, CH2Cl2, 0 °C to r.t., 3 h. 
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2.2. BDDE Binding Quenched the Intrinsic Fluorescence of α-Glucosidase 
The previously reported competitive inhibition on α-glucosidase in vitro [15] suggests that BDDE 
may directly bind to the active site of the enzyme. To test this hypothesis, we first investigated the 
BDDE induced changes in intrinsic tryptophan fluorescence of the α-glucosidase enzymes. As shown 
in Figure 2, when excitated at 295 nm, BDDE had no obvious fluorescence emission, and contributed 
negligible florescence interference. With the treatment of BDDE (0–100 μM), fluorescence intensity of 
α-glucosidase was quenched gradually in a concentration dependent manner. These results established 
that there is an interaction between BDDE and α-glucosidase, which induces a microenvironment 
variation for Trp residues in α-glucosidase. Possibly, this variation hinders the active centre formation 
and/or the binding of the substrates. The intrinsic fluorescence changes in α-glucosidase are similar to 
those in lysozyme induced by bromophenol blue [19], and many other enzymatic inhibitors could also 
induce fluorescence quenching of their target enzymes [20,21]. 
Figure 2. Intrinsic fluorescence spectra changes of α-glucosidase by BDDE. The enzyme 
(2 μM) was incubated with specified concentrations of BDDE (0–100 μM) for 30 min at  
37 °C. The excitation wavelength was 295 nm and emission spectra were acquired by 
scanning from 300 to 400 nm. 
 
2.3. BDDE Binding Reduced the Hydrophobicity of α-Glucosidase 
The hydrophobic characterization and environmental sensitivity of bis-8-anilinonaphthalene-1-sulfonate 
(bis-ANS) allow it to be widely used in measurement of protein surface hydrophobicity [22]. To study 
the BDDE induced changes on the hydrophobicity of α-glucosidase, bis-ANS was employed and the 
relative fluorescence intensities were shown in Figure 3. With increased concentrations of BDDE, the 
enzyme-bis-ANS fluorescence was reduced in a concentration-dependent manner. These results 
suggested that BDDE could reduce the hydrophobic surface of α-glucosidase. In our previous study, Mar. Drugs 2011, 9  
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reduced enzyme hydrophobicity were also observed when α-glucosidase bound to another inhibitor, 
butyl-isobutyl-phthalate (BIP) [23]. Such inhibitor induced decreasing in the hydrophobicity supports 
the notion that poor hydrophobic surface usually hinder the formation of active center in the 
enzyme molecules. 
Figure 3. Changes of α-glucosidase-bis-ANS complex fluorescence by BDDE.   
α-Glucosidase (2 μM) was incubated for 30 min at 37 °C in the absence or presence of 
specified concentrations of BDDE (0–100 μM). Bis-ANS (15 μM) was then added, and 
fluorescence was measured after 15 min of incubation at 37 °C (excitation at 400 nm, 
emission at 395–545 nm) using a Cary Eclipse fluorescence spectrophotometer. 
 
2.4. BDDE Binding Influenced the Secondary Structures of α-Glucosidase 
To study the effect of BDDE on the secondary structure of α-glucosidase, we measured the CD 
spectra (190–250 nm) of α-glucosidase. As shown in Figure 4, BDDE (0–100 μM) triggered a minor 
change in the CD spectrum of α-glucosidase, by increasing the α-helix (from 27.5% to 31.2%) and 
decreasing the β-sheet content (from 39.4% to 31.6%, Table 2). This finding further supports the 
proposition that BDDE binds to the enzyme and slightly changes the secondary conformation of   
α-glucosidase. The increase in α-helix induced by BDDE is similar to α-glucosidase inhibitor 
penicillamine, which also induces an increase in the α-helix content [24]. However, BDDE-induced 
secondary structure changes are in contrast to other α-glucosidase inhibitors, for example, 
curcuminoids analogs [7], BIP [23], and hydroxycoumarin derivatives [25], all of which decrease the 
α-helix content in the enzyme molecule. The reason that these inhibitors induce contrary changes in the 
α-helix content remains unknown. Nonetheless, it is clear that small conformational changes that 
hamper active center formation or prevent substrates binding will inactivate the enzyme. Mar. Drugs 2011, 9  
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Figure 4. CD spectra of α-glucosidase in the absence or presence of BDDE. α-glucosidase 
(2 μM, dissolved in 20 mM potassium phosphate buffer, pH 6.8) alone or incubated with 
BDDE (0–100 μM) at 37 °C for 30 min. Spectra were acquired from 190 to 250 nm. 
 
Table 2. The secondary structure content of α-glucosidase influenced by BDDE. 
BDDE (μM)  α-Helix (%)  β-Sheet (%)  β-Turn (%)  Random (%) 
0 27.5  39.4  7.1 26 
25 30.3  33.8  5.6 30.3 
50 28.9  34.7  8.3 28.2 
100 31.2  31.6 7.1 30.2 
The secondary structure content of α-glucosidase is predicted by program JWSSE (JASCO). 
2.5. Protein 3D Structure Generation and Molecular Docking 
Since the 3D structure of α-glucosidase is still unavailable, a homology model was developed based 
on the crystal structure of S. cerevisiae oligo-1,6-glucosidase (Figure 5a). To explore the potential 
protein ligand interactions, induced fit docking protocol was employed to dock BDDE into the glucose 
binding site of the non-cognate homology structure. The BDDE molecule was successfully docked into 
the active site with a highly favorable binding energy of −11.54 kcal/mol. The docked BDDE molecule 
was completely buried in the α-glucosidase binding pocket with part of the molecule reaching the 
catalytic center comprised of Asp214, Glu276 and Asp349 and overlapping with the position of 
glucose in its complex crystal structure, which adequately explains the competitive nature of BDDE; 
the remaining part of the molecule extended towards the protein surface. Using the same modeling and 
docking protocols, we have previously studied BIP, a non-competitive α-glucosidase inhibitor, and 
identified a novel ligand binding site located ~3 Å away from the catalytic center and close to the 
protein surface [23]. Direct comparison of the docking results of BDDE and BIP through structural 
alignment showed that there was no overlapping between the BIP and BDDE binding site, which Mar. Drugs 2011, 9  
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indicates potential non-competitive binding between these two ligands. Detailed structural analysis 
(Figure 5b,c) suggested that the binding pocket of BDDE consisted of three areas: (1) a charged area 
which is located near the active center and consists of charged residues including the negatively 
charged catalytic triads and positively charged Arg439 and Arg212; (2) a polar area near protein 
surface that consists of residue His279, His235 and Asn241; and (3) a hydrophobic area sandwiched 
between residue Phe300, Ala278 and residue Phe158, Phe177, Phe157, Leu218. While the hydroxyl 
groups at the two ends of BDDE molecule formed multiple hydrogen bonds separately with residues in 
the charged and polar areas, the rest of the molecule were stabilized by hydrophobic interactions with 
nearby residues. The observed multiple hydrogen bonds formed by the hydroxyl groups of BDDE are 
consistent with the conclusion from previous studies that phenol moiety and hydroxyl groups in 
hydroxycoumarin derivatives are critical for their inhibitory activities [25]. The identified   
charged-hydrophobic-polar (C-H-P) binding pocket, which fits very well with the symmetrical feature 
of BDDE, provides structural insight for design and development of novel α-glucosidase inhibitors. 
However, further X-ray or NMR data are needed to verify this enzyme-inhibitor binding. 
Figure 5. Structure model of BDDE-α-glucosidase complex. (a) Comparisons between 
docked BDDE (green-carbon), BIP (blue-carbon) and the crystal structure of glucose 
(yellow-carbon). Glucosidase is shown in grey ribbon, ligands are shown in solid sticks, 
the triad residues (Asp214, Glu276 and Asp349) are shown in a CPK model;   
(b) A close-up view of BDDE binding pocket. Molecular surface are shown and colored 
according to their residue properties (red: negatively charged; blue: positively charged; 
cyan: polar; green: hydrophobic); (c) The interactions between docked BDDE and nearby 
residues. The triad residues are emphasized in a ball-and-stick model, and hydrogen bonds 
are represented in dashed yellow lines. 
 Mar. Drugs 2011, 9  
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3. Experimental Section 
3.1. Materials 
The baker’s yeast α-glucosidase (EC 3.2.1.20), p-nitrophenyl glycosides, and   
bis-8-anilinonaphthalene-1-sulfonate (bis-ANS) were purchased from Sigma-Aldrich Chemical   
(St. Louis, MO, USA). Other reagents were reagent grade available and purchased from   
J&K Chemical Ltd. (Beijing, China). 
3.2. Synthesis of BDDE 
Procedures for the Preparation of Compounds 1 to 7 
3-Bromo-4-hydroxy-5-methoxybenzaldehyde (2). To a solution of compound 1 (15.2 g) in 
AcOH, Br2 (7 mL) was added at r.t. This mixture was stirred at r.t. for 2 h, and the compound 1 
disappeared by TLC. Then the mixture was poured into cool water, and after filtration, the product 
compound 2 was obtained as white solid (20.7 g, yield: 90%). 
3-Bromo-4,5-dimethoxybenzaldehyde (3). To a solution of compound 2 (20.7 g) in CH3CN, 
K2CO3 (19 g) and MeI (19 g) were added at r.t. Then this mixture was stirred at r.t. for 4 h. The 
mixture was poured into water and white precipitation was showed and the compound 3 was obtained 
after filtration as white solid (20 g, yield: 92 %). 
2,3-Dibromo-4,5-dimethoxybenzaldehyde (4). Br2 (7 mL) was added to a solution of compound 3 
(20 g) in AcOH at r.t. This mixture was stirred at 60 °C overnight. The TLC showed the compound 3 
was consumed completely. Then the mixture was poured into cool water, and after filtration, the 
product compound 4 was obtained as white solid (19.3 g, yield: 73%). 
(2,3-Dibromo-4,5-dimethoxyphenyl)methanol (5). To a solution of compound 4  (19.0 g)  in 
MeOH, NaBH4 (4.52 g) was added at −20 °C. Then the mixture was warmed to r.t. slowly and stirred 
for 3 h. After removing the solvent, the product compound 5 (13.3 g, yield: 70%) was obtained by 
washing with water. 
5,5′-Oxybis(methylene)bis(3,4-dibromo-1,2-dimethoxybenzene) (6). To a solution of compound 5 
(13 g) in CH3CN, 4.54 g of TsCl and 2.41 g of Et3N were added at r.t. Then the mixture was refluxing 
overnight. The TLC showed that compound 5 was completely consumed. The mixture was poured into 
cool water, after filtration, the product compound 6 was obtained as white solid (6.56 g, yield: 52%). 
Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether (7). To a solution of compound 6 (6.0 g) in dry 
CH2Cl2, BBr4/CH2Cl2 (2.0 M) solvent (20 mL) was added at 0 
°C. The mixture was warmed to r.t. 
slowly and stirred for 4 h. Then, cool MeOH was added to quench the reaction. After removing the 
solvent, the residue was separated by biotage® Flash chromatography (35% MeOH/H2O) to obtain 
compound 7 (1.2 g, yield: 21.8%). Mar. Drugs 2011, 9  
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3.3. Intrinsic Fluorescence Measurements 
α-Glucosidase (2 μM) was pretreated with certain concentrations of BDDE (0–100 μM) for 30 min 
at 37 °C. The intrinsic fluorescence spectra (300–400 nm) were measured using a Cary Eclipse 
fluorescence spectrophotometer (Varian Inc. USA) with the excitation wavelength was 295 nm.  
3.4. Hydrophobic Analysis of α-Glucosidase Using Bis-ANS 
α-Glucosidase (2 μM) was incubated at 37 °C for 30 min in the absence or presence of certain 
concentrations of BDDE (0–100 μM). Bis-ANS (15 μM) was then added, and fluorescence was 
measured after incubation at 37 °C for 15 min (λex = 400 nm, λem = 395–545 nm) using FlexStation II 
microplate spectrofluorometer (Molecular Devices, USA). 
3.5. Circular Dichroism Spectroscopy 
CD spectra (190–250 nm) of α-glucosidase (2 μM) treated with different concentrations of BDDE 
(0–100  μM) were measured with a JASCO 715 spectropolarimeter (JASCO, Tokyo, Japan). The 
spectra were collected and corrected by subtraction of a blank containing 20 mM potassium phosphate 
buffer (pH 6.8), reduction of noise, and smoothing. The program JWSSE (JASCO) was used   
for estimation of the secondary structure percentage of α-glucosidase based on the method   
of Yang et al. [26]. 
3.6. Molecular Modeling and Docking 
Molecular modeling and docking studies were performed following the similar procedure as in our 
previous study [23]. Briefly, a 3D homology model of Saccharomyces cerevisiae α-glucosidase was 
built based on the complex crystal structure of α-D-glucose bound oligo-1,6-glucosidase (PDB ID: 
3A4A) which shares 72% identical and 85% similar sequence with α-glucosidase. Sequence alignment 
and structural model building were performed using the protein structure prediction suite Prime 
(Schrödinger, New York, NY, USA). The constructed homology model was further optimized using 
the protein preparation wizard of maestro 9.0 with OPLS2001 force field [27]. Docking studies were 
then performed on the optimized model using the Induced-Fit-Docking (IFD) workflow [28], which is 
capable of sampling dramatic side-chain conformational changes as well as minor changes in the 
backbone structure. Specifically, the center of glucose molecule in the crystal structure was selected as 
the centriod for ligand-docking, residues within 6 Å distance of glucose were set to be flexible. IFD 
protocol was applied with default parameters to sample energetically reasonable side chains and to 
eliminate conformations with steric crashes. The docked protein-ligand complexes were ranked 
according to their IFD score made up of the protein-ligand interaction energy (GlideScore) and the 
protein molecular mechanics energy (Prime energy) in an implicit solvent model [28]. Mar. Drugs 2011, 9  
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4. Conclusions 
In summary, BDDE has been synthesized and its interaction with α-glucosidase was studied. Our 
results suggest that BDDE bind the enzyme molecule via both hydrogen-bonds and hydrophobic 
interactions. BDDE binding hindered the substrate from accessing the catalytic site and induced 
conformational changes on α-glucosidase, characterized by intrinsic fluorescence quenching, 
hydrophobicity reduction, and α-helix content increase. This study provided structural insights 
regarding the interaction between α-glucosidase and BDDE, and implied that BDDE could be 
considered as novel template for the design of α-glucosidase inhibitors. 
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